News for Cue Biopharma, Inc. (CUE)

On December 31, 2024, Slate Path Capital LP (Trades, Portfolio) executed a significant transaction involving Cue Biopharma Inc, a clinical-stage biopharmaceutic

BOSTON, Mass., Nov. 29, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. ( CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeuti

BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. ( CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biolo

Cue Biopharma (CUE) delivered earnings and revenue surprises of 15% and 205.22%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

**media[466687]**

**media[460629]**

Canada-based ZenaTech, Inc. (ZENA) is up over 72 percent in Friday's pre-market trading. The following are some of the other stocks making big moves in Friday's pre-market trading.

Cone Biopharma (CNTB) experienced a significant stock drop of 5.47%, currently trading at $1.21 per share. The trading volume reached 777 shares, with no notabl

Cue Biopharma authorizes more shares

Lexicon Pharmaceuticals (LXRX) experienced a notable stock movement, with shares rising by 5.59%. The stock is currently priced at $1.70 per share, with a tradi

The US stock market opened higher on Friday, September 27, as soft inflation data fuels investors’ expectation of further interest rate cuts from the US Federal Reserve, according to the news agency AFP.

Shares of Clover Health Investments, Corp. (NASDAQ: CLOV) rose sharply during Wednesday’s session after the company reported better-than-expected fourth-quarter revenue results and issued FY24 insurance revenue guidance.

The Dow Jones closed higher by close to 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

BOSTON, April 12, 2023 -- Cue Biopharma, Inc. , a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific... | April 12, 2023

BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...